to you sharing in Roivant’s the to a joining everybody, some thank business. for ever updates first and be be today our about earnings pleasure Paul morning, call It’s Thank and and good talking to you, history. you
and be from a X we’ve the building. we’re to redefine of a Before on particular what family end-to-end, in why Yes, we’re who Roivant’s quarter, with excited different a said is Roivant of can the small of pharma better companies I biotech Page a we’re since we enable want focusing data model, I differentiated Vants do I a the improve with, way here pipeline new as novel big about our is company that quite we to that business. reminder and talk business think beginning X, organized of broad just on to talent start of computational commercialization Starting in a a on Vants, nimble of about business. history what number of we’re the using the key that technologies as entrepreneurial we medicines. highlights us with and a and On well in discovery, focusing to tools highlight as have that our at development call of number some Page which
quarter. of September We with the billion cash a are well funded end balance the at $X.X
have We novel today do best-in-class capabilities, some and A in of field particular molecular about it. the to platform better discovering, spend us for full talking later more chip-to-clinic we degraders. in discovery dynamic believe computational time which we’ll protein at enable simulations, job a simulations, with
revenue with $XXX as siloing which stakes improve million which the equity in we assuming year, our value built healthcare a to Ciox that [ph] an this is clinical Datavant, businesses built of in transaction. this earlier we Health, may additional time we and now problem that was top called Vants over order received own in important line for billion that value, business a XX% million [indiscernible] by public cash And Datavant that grow data in We a a of and you dollars we that transaction into $XXX in value in solve Datavant, we Datavant the approximately which $XXX as And and investments is including proceeds, to healthcare stake, have to holdings, a as made the collection company expect merged stake Sachs over needed business know, of data time. XX% development. private other approximately plus well by ownership in $X implied Goldman million we
stake eight addition of dermatitis. molecule opportunity our of development least that lab, four small Phase we of provide highlights integrated and in the of at financial computational continue our we’re little drivers little including in resulted our an tapinarof the on partner seven revenue, topics information an bit value the optimize. all a ownership going for business outline degradation. us for talk which an update of or X overview give for in is, year. discovery $X.X to most expected approved advanced a to of Page ongoing update focused other we’re pipeline, Sumitovant. four our our wet our that’s a performance with and further the well important FDA opportunity on launched XXXX model trials just that field a some planning now finally, growth be cover with progress to And future. a I’ll is And protein now trials So by Roivant by believe strategic out starting drug have expected X in On and that initiation And read as further nine what with track launch have build as atopic expect products, to phase studies I’ll I’ll with by for targeted billion, end platform with X run has clinical in and metrics. by Vant excited on and our of about in some by I’ll quarter, an of things providing we for of we’re pharma including to to to owned having have in to commercial the importantly, record, today, about positively, the plans psoriasis development company, total, again, clinical in our cash launch capabilities bit a that strong of of end brief three providing balance our be to we registrational whichever couple is key
you very thank at there’ll be for the Paul call. as indicated, end an Q&A So and of opportunity the much,
that, of to the quarter going I’m topical therapy where start PDUFA for we second filed expect with psoriasis, action treatment Datavant’s discussion Page NDA on where tapinarof. a X a in with of the So we of XXXX. our and
an obviously it for extremely So is feel new a we differentiates about medicine key therapy excited are this as psoriasis promising attributes. it patients. that that view We five and incredibly along we
then complete PGA degree attribute showing showed significant of extension score on even our of and with of performance clearance second the continued in That’s achieving including therapy used we treatment systemic measure endpoints, to the of is of long including statistically disease in tachyphylaxis and X. study a our data strong durability, summer of perhaps tapinarof, endpoints is no high XXXX, the first program, clearance, continued patients study. Phase X long key gets demonstrated term -- of our extension effects. exciting, all therapy. in disease about a important which read performance XX% X out We of more over term improvement, The during the to the typically performance And which evidence
effect. its of tapinarof differentiating is third important attribute remittive The
treatment, is in or data XXX And extension their about them. a on no tolerability, avoids again patients them quarter. that no off they from we is serious days, events related namely study with presented issues a mainline safety approved previous When this score unheard XXXX or or our effectively which our therapy stayed they cleared and therapy mean patients clear that, any long with PGA topical term achieved or current a in studies our long finally the psoriasis, for of current and of then safety topical different study use skin of XX for location topical this associated our with took corticosteroids opinion remittance; the trials monitored therapy mostly extension all so of and consistent adverse talk studies saw of in the many of which across was we’ll treatment a duration with something months, with therapy. of And and profile over little in which a clear limitations corticosteroids. in we tolerability term is and is enrolled our of critically this that in zero, is And duration four when bit category clinical more psoriasis
people to globally a that in little two a think provided I’ll as atopic want remind I program and XXXX, XXXX. over So, X, these America in XX% represent markets we registrational psoriasis clinical in important these in over that of for are markets an mentioned as in have bit where the And program, I about largest later. and everybody expected two written dermatologic $XX as that decision bedrock a by the we targeting with, think where reach one topical are dermatitis, $XX U.S. by U.S. of familiar expect attributes billion currently first serve which which XXXX. all billion half are today, of the the are underway tapinarof’s talk treatments dermatologists to are I five treatment in approval is of prescriptions well that is really Page we most a On differentiation. reminder tapinarof I immuno-dermatology,
results much I the brief be of type nature PSOARING we reminder a of personally this long-term both out myself given as both we these say the a Page what briefly experienced symptoms XX, which psoriasis of community. psoriasis quarter, On the on X, study. expect our many and that some a ago And it well both look So of want most extension I’ll data atopic provide will data I briefly adult new is that don’t I of to diseases, as and but includes EADV highlight that are I overview to is I think therapy for patient incredibly at to presented need of common these of like. impactful have Page psoriasis life. am time these the some put we a dermatitis my this of data so and X
of study of psoriasis. both excited and tapinarof the And the completely consistently So on or study. am want that treated a effect their this is of with became patients to highlight one this total to that clear particular, I XX was program XX% is in LTE which LTE the observed, weeks. patients patients most And about, monitored trial that I achieved of score therapy who of clear was up for effects in a cleared the entered PGA a zero, during the the
effect study is and in saw we our this our to significant study exciting repeatable that extension in that us. a was Phase So X
monitored off presented therapy, them of mean on remittive which them a when or long-term duration we that team therapy PGA almost zero, we of mean without I’ll took remittive extension the achieved important Page the EADV, treatment the clear effect. at clear zero describe the is I’ve days. what of again, in with XX, benefit study of days, off to significant at subjects across again, and patients EADV, this and stayed during the These we XXX achieved who for equally PGA was patients that a once the happened. entered extension observed Now, we it but or additional Dermavant The is see And XXX call, a XXX score that a data that’s mentioned study. took some of beginning presented patients
time, overall remaining in going for well are corticosteroids these when which a disease are what profile clearing more corticosteroids, observe is that for and And psoriasis significantly you which their and we’ll different are on differ. than you example cease tapinarof moment with have treatment. a burden, of the talk effect we rebound So patients how long about then a are
and corticosteroids. with, topical on patients So, current main that psoriasis XX, line very may Page am this therapy I know, personally as you something for is the familiar is
And my cabinet This partially limitations. tubes is used filled topical have medicine therapy of is for with all really standard corticosteroids. corticosteroids So patients. significant some
benefit. of skin. are restrictions, off long psoriasis safety effect. thin most addresses they the They ups. of where rebound tolerability have you use which basically the skin use location that the thinning tapering therapy, sort And time can’t can’t because reason cause all sensitive. them the with You issues, are a of quickly for use durable that of parts When a effectively for these example, don’t of to go limitations. you there have tend are Tapinarof and flare There’s off they steroids you on potent already or duration and a
have We corticosteroids. studies than is that good been better efficacy ever what as observed or of has topical in
patients drug the on extension durability, stay longer continues We study. have true the our to where work therapy better it on in our
remittive We have effect. a
issues, observe stay significant in patients are that on view my use and can and our study, when then stay but unlike as you therapy topical you by that see in canal. rebounds observed means for And you chronically, than anywhere effects more So it the not have our tolerability amount we long you long XX-week tapinarof and benign psoriasis ear corticosteroids, you only without for is my for outer time. frankly our stay on skin the can thinning corticosteroids profiles go other on a we time. safety that so clear patients the with said the topical can And in that what a off, skin in I want example, severe a and most you
no of has tapinarof but limitations. there, corticosteroid potent a use location use can’t You
to therapy a tapinarof’s past of the a treatment as dermatologist to psoriasis. so. Obviously, decade have Now, the possibility or for for the received speak all communities attention psoriasis lot of and that investor systemic line of main over from is medicines
to The we when that typically new therapy line as setting. other with along as receive prescription psoriasis addition a these severe therapies diseases, put therapy, for that main tapinarof’s observed to as a biologics thing severe get in systemic or it we systemic a also And psoriasis, is, in well. with possibility a two-thirds good patients on moderate ultimately topical and see even partner
XXXX, study shown important here includes the of patient to began a significant as a Phase expansion XX, expect the program mostly that all speaking potentially in year, number of the is data think we on X. population currently once so On patients, down first the decision, reminder, said way we data from also where dermatitis. X tapinarof expansion was this we to the I’ll on Phase it’s Page patients study two an so we includes this age a highlight the running and I out. and in study earlier Phase tapinarof data XX, as we comes are We a The XX, statistical X design studies first several which patient to we in a results reminder, Page of So, atopic study population. we our week Phase significance see conducted the X of approval expect psoriasis in the possible And here that show X and on at achieves have endpoint. already atopic Page dermatitis on half of
And is, The prospects the in on about to the from atopic I’ll Dermavant, excited that you’ll thing XX, we’re study. extraordinarily end where on hear our with number day I every So field leadership better from drug prepare our have deep model launch chance tapinarof’s dermatitis experience and are launches the for pending ability extraordinary Page him, for have could teams a multiple Q&A therapeutic a a to team approval is one of recruit they the within product keys the overseen decision. expertise. of in companies. Todd to choose of the deep And success not of Vant Vant area areas dermatology. in example is this and of to have blockbuster of the indicative whole, with the specific across from Dermavant They our and portfolio model a hard his working this in Todd as
this for So the incredibly the I you to leading but are a is quality of optimistic about from Q&A that the we program, prospects hear have today, team chance think the during know, Todd it. you’ll given
pipeline, that some development. here, of on development at So are including the major breadth is today, late-stage in clinical our the reminding go topic talk going I’m people I’m which the of going programs about to from in to for next to progress stage
you reminder, and of includes our number So on therapeutic XX, different therapies, span which know, by see can pipeline, these a stage development see flexibility a afforded areas, can modalities. that the different you you per they the Page model, span as Vant
across kinds therapeutic we us we of we afforded model. We we oral the of is have different to agents Vant a that’s agents, feel small topical by have biologics, some have flexibility have and number molecules, categories that antibodies,
as is Page also batoclimab, antibody our the on at XX, reminder being studied of anti-FcRn progress known on start I’ll which IMVT-XXXX, So Immunovant. a with and
a has you is public as and recently. their also Immunovant So own provided company know updates
administration for this to possibility has some simple key the in-licensed rapid with with a theses the from anti-FcRn it in batoclimab patient was diseases. populations particular the deep, beginning. differentiating flexibility very And patients true and winds large in attributes, market. excited of And think that of including obtain flexible target, then important being dosing sort we the a by the think mediated term, is of long-term. And was affecting fundamental the in injection. We that are adjust these it. in IgG an with And to We that which route pathogenic of subcutaneous we these biological very simple diseases administration with IgG of straightforward route ability suppression thing it treatment for and one potential designed And the important on the short with quite that’s suppression up autoantibodies.
here. As people they they about that therapy, indications the sort other and flexible attributes to about matter think that of about in are think going of relevant we and often are rescue think induction, think dosing
developing two development next feedback And designs bit starting quarter So Vant is we a finalizing about and XX, our on trial of Page year. this clinical provide FDA expression the delivery a said have -- observed. we providing modified driven gene cell our a has plans therapies disease, in for is it a we modified which remains that therefore on talk initiate we therapies alone. piece feedback what which this to And is intensity of Immunovant But we full said and programs do is our by efficacy get spend important. number has which the think gene Lentiviral by even I ARU-XXXX, FDA, about one reduced there, that this, and next with fetal therefore and required than an that And little a fetal our final better potency properties what diseases. particular trials rare are to update the us gene. to will are we’ll of of we’ve few anti-sickling less this from so better true gene than program of a so conditioning, for in hemoglobin Aruvant, clinical to allows talk forward other particular, rather the outcomes on in Immunovant with awaiting batoclimab update and minutes allows plans, that to we proposed and the look that on critically, unique that we And and sickle it we’ll by myeloablation of from year even before for us end will more form in development. therapy continuing the hemoglobin and the expect
that months. care talk bit currently in through IND enzyme or enabling it in And durable replacement our adeno for be nonspecific gene therapy we’ll alkaline chronic one-time XX viral studies the data ongoing. has with of about And to hypophosphatasia more phosphatase shown increases prescription a So replace the then tissue which standard possibility Aruvant, an as a preclinical in therapy program therapy ARU-XXXX one-time program. has I to other
study and the can XX And and had many vaso-occlusive first our work were are significant different XX, as patients as that different this our we before. talk XX, patients a over of of in including that a supportive baseline and that a number Children’s care, improvement two pre-treatment these patients period Page development on. Phase at see, we were quite two-year therapy sick number It’s three, patient ARU-XXXX. And on in-licensed observed little failed So bit events process of we’ve efficacy want reminder, transfusions Hospital. you Pages to between on kinds pre-treatments, these with hydroxyurea, began patient the Cincinnati from and when four I about in a X/X to in so
these disease, observed are and a our you is XX, patient no extremely patients on our date, vaso-occlusive a of are of severe vaso-occlusive XX months XX case can the R&D academic three, that improvement From to we Even we sickle effectively of so patient the update four, about. Page the what in So we events, these so complete that few in observed case and patients. patients. we through the through September, and original of events a in first event cell months the on symptoms excited condition at elimination manufacturing patients complete dramatic this of six in clinical provided in observed something have cell these process cure the see near of sickle
use the sickle other for and this which and may this I out exciting a Now, highlighted treatment allow cell fetal intensity approaches there. that with field, that exciting hemoglobin to therapies for number a of preconditioning and something are key know designed editing disease The it genetic difference from on us the you our there idea is regimen. following developing therapy, there Page reduced are ago, originally gene modified medicines promising was gene form there is moment a XX, are of would people the of
patients spending does directly therapies the regimen. in are base melphalan issues associated any this so ablative this hospital. conditioning, actually form as using a a using of And preconditioning longer tolerability ablative matter? reduced experience we agent, fetal And I we dramatically the the melphalan in regimen of busulfan mal conditioning what, using relate a of are able mal been these why to therapy demonstrated modified preconditioning. hemoglobin, have of because you that using with patient know based the case And to clinical aware of or the this an of busulfan, whereas dose the data short, of that in intensive mean, have on therapies other data these with our all intensity most
possibility somewhere that time is So between XX versus this melphalan procedure and our median with approved. the will outpatient days five on that’s product zero the by days be for
a patients, these immune know, risk you to significantly associated its instead reduced busulfan is of are sickle with risks one seeing XX% XX%. young Remember, XX% XX% cell to failure. the ovarian suppressive. And of are major of We enormously
are And been significantly that and at associated risk over melphalan risk. with is reduces then malignancies purely also with for that time is patients, issue preconditioning. infections faster recovery much be so, busulfan who much, also secondary and busulfan based And secondary significant studies preconditioning based much, these of significant associated a in time
So our very to is development make community matter sickle differentiated for cell the differences prediction cell these that enormously will even the amongst and profile, a for in patient sickle curative disease. genetic medicines
mentioned, So Phase X/X in study our is right now. as we’ve this
We study. continue in to that enroll patients
We into next to expect year. to continue patients enroll
data We those we will our and the XXXX. a to Malik updates. expect provide updates are of ready continue we at new the including And in beginning provide on Poonam is with additional as weeks this in the Conference the get ASH patients making coming to program presentation study some data, pivotal into ARU-XXXX we investigator, to a on put
options, event in year. remain many X and patients. kind an on that’s as Immunovant more initiate that antibody Phase expect current comparatively We track we time of treatment half in four some we namilumab, at initiate guided, trial about sarcoidosis, a X this will studies multiple And XXXX, spent studies as, doing in batoclimab multiple a X with in to have not start least portfolio, indications, anti-GM-CSF important program, but across we our talking as our disease well including or our across with the first has XXXX. in to the So monoclonal poor new lot Phase of pivotal
that license again, excited aureus bacteremia, trial forward something we year speaking unmet significant and treatment next it’s as begin in well again, trial about, of our that we’re as more so for potential address Staph looking And to need to could is X LSVT-XXXX, that Phase novel are which into as well.
our on we And look been which first clinical today about moving want in and providing from all, the in-licensing. assembled to going also as provide of basis. continue we historically, on about our important our them. as have forward to talked approach reminder, updates to much and pillar of is discoveries, our by forward programs development strategy a of a we many important, a I So, has an drug programs, stage reminder pipeline of
often, which even to So we thesis out to boiling we we are add our teams to pipeline. based -- an responsible And programs that the a take we’ve figuring have several and new the that ocean, opportunity past approach looking programs target for excited over And nothing targets fit when we’ve repeatedly years, the in-licensed identified. we’ve opportunities said, for therapies bill. quite issues as about we where match gotten the were that for look
so invest and in-licensing that programs could broader ago a that platform of identified. a in years discovery And us to we’ve started our set we number of efforts complement work allow to on a
the of learning, combining allows dynamics simulate including motions, calculations and schematic like. do a platform And both, what to we AI about complexes, platform, that so of protein and of for in EX signaling. kinds on and of and looks searching just I’ll allosteric a of as bias molecular a including all novel and Page And this to us free XX combination simulation achieve necessary ligase biological is most protein which that as it believe agonism, the And well, precise is sort talk discovery machine energy critically, ternary includes a drug we is binding sites, believe leading degradation. moment, computational
the predictions area important protein degrading successfully the one a we of targeted degradation. protein, reasons which ingredients are So make on focused to is of in of the
computational us folks area, has and platform this have the enable with Chief of and wet Scientist, a Woody generate combination that with teams facilities Silicon Now, our biophysicists biophysical in chemistry platform data, made to many and who of computational Computational vis-à-vis a wet for this the been think now integrate addition degrader engine to we don’t to in an in to been ingest provides from there any tools. have believe computational our a lab biology, side, loop, and designed across has to on world-class to And that we building responsible like which us generation kind necessarily complement of other of wet who and the lab, world-class computational has acquisition then the team of Therapeutics, version and incorporate world-class for, lab well comes working chemists feedback data, number lab algorithm Sherman, tools, for specifically biophysics of companies, as investment computational we as with the itself, engine wet discovery. our that example, worked haven’t this of time, out focused real that different of critically computational novel that he the Schrödinger vis-à-vis important the biologists, area, differentiation, other the long molecular dynamics that at most and ability data, next this built team extraordinary tools by companies
unique us gives the it position in landscape. degrader So a
So I I features instability protein of to of which on in our simulate there, be important we degraders. the the and novel based potential highlight and ability mentioned formation, before, which ternary has is to Page important of design complex one XX, this think binding structure very
of designs recruit start magnitude this so an to most the make and conformation of the made a which with the in turn ligase EX ever we ternary and that a of with simulations effectively maximize can stabilize degradation. accurate formation, of think, complex So and about the is, which degrader degrader, will and probability position most we will predictions combination protein those
show our discovery in of So, already number stage actively pipeline. Page we tools and XX programs, using degrader our a on are these we
stage So our we development spoke previously about pipeline.
program, inhibitor other will androgen programs degrader, a Discovery, Roivant targets number other occasional modalities highly have across also we receptor clinically Proteovant across but targets, in programs between we think be and principally XXXX, degrader novel validated across from targets degrader ranging our of clinic in be which or programs have of opportunity our expect the to in combination like to small molecule the where We biologically and an validated we first a either the pipeline, first of best-in-class.
we on to these and excited to programs our advance discovery preclinical continue So provide efforts discovery. updates other through as
about for to our want a say results XX word I So financial on quarter. the Page
SPAC funding of merger that billion increase was of quarter was September and the all, time of driven cash it $XXX as $X really closing this that increased XX, cash was things. It consolidated And the by by received, of was driven the first opposing our that of So, in by three Health, invested earlier. about to with it from driven Proteovant $X.X million million equivalents talked our June transaction, XX. Ciox driven as by Holdings, and of I we cash the second in SK Datavant $XXX at the by proceeds billion
so was for As the our expense far expenses million. R&D adjusted for quarter quarter, non-GAAP the $XXX our as
non-GAAP non-GAAP the and commercial for this and based presentation. made reconciliation the said, we cash adjusted in probably of for and of outstanding I adjustment the we that of led to the, approximately million million, $XX XXXX. appendix the And at full XX, highlight we transaction, with November almost was expense one $X.X provided, equivalents approximately the related $XXX net in in most SPAC tapinarof. Our of we finally, share so common adjusted expense quarter Dermavant to It of $XXX see that $XXX adjustments entirely quarter loss charge. the the get I’ll closing a billion And as a And was then significant that this of $XXX to obligations G&A of million. you approximately milestone million one-time GAAP significant end cash shares million quarter, we’ve had as compensation a to is relatively non-GAAP the was then for can and that quarter, debt have related the that of
remind Q&A, expect to weeks we the want turn I relatively in couple for about of just of to coming opportunities more everyone to we that growth and months. speak before So, near-term a
around today. a our conference and LNPs on generally. this activities And acid of dating scientific And therapeutics I in which the we well talk Page Roivant where advance interesting. portfolio the nanoparticles is, chance in earliest of new would and a XX, identified programs speaking today, working development that that of about some we’ve the other board the of to schematic generation number have today, we’re opportunities, as a and team I to about potential activity, our field. so are to area flag, to collaborations you presentations have a other back next Genevant, have to exciting is future, our Vants is an There And slide, of so we had a about few manufacturing estate. novel that in-licensing forums, that to particularly extraordinary and that many then in as, launch look not more talked see an on do including we nucleic forward there, we’ve we of called liquid Vants platform can and am them out some that Vants more describing that around think Vant of are scientific we expect so involved in has working LNP of a excited deliver One really but we near been number and on important IP collaborations chemists to about
will program today mentioned about that going to more but in-licensed in well. we’ve future, one fact, In be the talk we’ve such there that near we’re others as
updates I about excited share excited to them. So, and come those am to
of top XX, final we includes of data as, program on multiple rich psoriasis, approval out a updates indications upcoming and that reminder trial that FDA Aruvant and programs, set line As and the dermatitis. IMVT-XXXX announcing those new on the discovery chemical X/X the Immunovant, well series there, a on initiation beginning next just from more multiple and initiations of ongoing activities. of provide on preclinical data coming programs our including trial multiple other Phase Page Phase the year, decision in upcoming re-initiation mentioned, continued highlight as And different to X complete our catalysts of well. includes for tapinarof tapinarof our well about X It our and Phase then, to as batoclimab, as atopic as clinical opportunities trial have I as and detail want of updates
back we at the call to And important for and operator the opportunity that forward and excited So, we for for look today updates year the want will taking the I Q&A. want the time thank over have of wrap-up We presentation to taking point and to this every we to them. about think portion continue of number communicate to and I ahead. everyone quarter a are hand we to this can the listening
look I thank So forward and taking your to you questions.
